Targeted Cancer Treatment Using Light-Activated Medicines
Site Specific Drug Delivery with Light-responsive Conjugates for Photo-biomodulation
This project is developing new ways to deliver cancer medicines directly to tumors using light, which could make treatments more precise and effective.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University of New York at Buffalo NIH-funded |
| Lab location | 1 site (Amherst, United States) |
| Project ID | NIH-11145137 on NIH RePORTER |
What this research studies
This project aims to create special chemical links that release cancer drugs only when exposed to specific types of light, like visible or near-infrared light, which can reach deeper tissues without being toxic. These light-activated medicines are designed to target cancer cells and release their drug payload precisely where needed. The goal is to not only treat the tumor locally but also to activate the body's immune system to fight cancer throughout the body. This approach builds on previous work that successfully showed how to create and activate these drug conjugates.
Who could benefit from this research
Good fit: Patients with certain types of cancer, such as bladder or breast cancer, who might benefit from highly localized and immune-stimulating therapies, could be ideal candidates for future applications of this technology.
Not a fit: Patients whose cancers are not accessible to light-based therapies or who do not respond to immune system activation may not directly benefit from this specific approach.
Why it matters
Potential benefit: If successful, this approach could lead to more targeted cancer treatments with fewer side effects and potentially activate the body's own defenses against cancer.
How similar studies have performed: Previous work by this team has successfully demonstrated the basic concept of light-activated drug release, indicating a foundation for this advanced strategy.
Where this research is happening
Amherst, United States
- State University of New York at Buffalo — Amherst, United States (Active)
Researchers
- Principal investigator: You, Youngjae — State University of New York at Buffalo
- Study coordinator: You, Youngjae
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.